...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pain & palliative care pharmacotherapy >Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
【24h】

Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.

机译：缓释和长效阿片类镇痛药的风险评估和缓解策略（REMS）：姑息治疗的考虑因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prescription opioid analgesics are an essential treatment option for patients with moderate to severe pain. Over the last decade the increased medical use of these agents has contributed to a public health epidemic of abuse, addiction, and overdose-related deaths. These medications remain mainstays in both primary care and pain management practices. As palliative services are incorporated at earlier stages of the disease process and the number of individuals with chronic illness increases, palliative care specialists may encounter an increasing number of patients with opioid abuse and addiction problems. Extended-release (ER) and long-acting (LA) opioid formulations are administered to patients with moderate to severe chronic pain requiring around-the-clock analgesia. Given the large quantity of active ingredient contained within some dosage strengths, this medication class is associated with serious risks when taken improperly. In response to growing reports of abuse and overdose deaths, the US Food and Drug Administration (FDA) announced the need for a risk mitigation strategy for the entire class of medication. The class-wide Risk Evaluation and Mitigation Strategy (REMS) for ER/LA opioids will emphasize prescriber training and patient education to ensure that the therapeutic benefits outweigh the risks of addiction, unintentional overdose, and death. As primary care, pain management, and palliative care clinicians often encounter patients who require ER/LA opioids, an understanding of the suggested requirements and potential impact of this regulation is essential.
机译：处方阿片类镇痛药是中度至重度疼痛患者的基本治疗选择。在过去的十年中，这些药物在医疗上的使用不断增加，导致了公共卫生中滥用，成瘾以及与药物过量相关的死亡。这些药物仍然是初级保健和疼痛管理实践中的支柱。由于姑息治疗是在疾病过程的早期阶段进行的，并且慢性病患者的数量也在增加，姑息治疗专家可能会遇到越来越多的阿片类药物滥用和成瘾问题患者。缓释（ER）和长效（LA）阿片类药物制剂用于需要全天镇痛的中度至重度慢性疼痛患者。由于某些剂量强度内包含大量活性成分，因此，如果服用不当，此类药物会带来严重的风险。为了应对越来越多的关于滥用和过量死亡的报道，美国食品药品监督管理局（FDA）宣布需要针对整个药物类别降低风险的策略。针对ER / LA阿片类药物的全班级风险评估和缓解策略（REMS）将强调开处方者培训和患者教育，以确保治疗益处超过成瘾，无意用药过量和死亡的风险。由于初级保健，疼痛管理和姑息治疗临床医生经常会遇到需要ER / LA阿片类药物的患者，因此必须了解建议的要求以及该法规的潜在影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号